Artivion (AORT) Projected to Post Quarterly Earnings on Thursday

Artivion (NYSE:AORT) is expected to announce its earnings results after the market closes on Thursday, February 20th. Analysts expect the company to announce earnings of $0.12 per share and revenue of $100.82 million for the quarter. Investors that wish to register for the company’s conference call can do so using this link.

Artivion Price Performance

NYSE AORT opened at $29.93 on Wednesday. The firm’s fifty day simple moving average is $29.80 and its two-hundred day simple moving average is $27.70. The company has a current ratio of 1.88, a quick ratio of 1.33 and a debt-to-equity ratio of 0.71. Artivion has a 12-month low of $18.38 and a 12-month high of $32.33. The firm has a market capitalization of $1.25 billion, a P/E ratio of -1,496.50 and a beta of 1.75.

Analyst Upgrades and Downgrades

Several equities analysts have issued reports on AORT shares. Oppenheimer lifted their price target on shares of Artivion from $30.00 to $32.00 and gave the stock an “outperform” rating in a report on Friday, November 8th. Needham & Company LLC reaffirmed a “buy” rating and issued a $34.00 price target on shares of Artivion in a report on Tuesday, January 28th. Finally, JMP Securities reaffirmed a “market outperform” rating and issued a $33.00 price target on shares of Artivion in a report on Tuesday, December 10th. Five investment analysts have rated the stock with a buy rating, Based on data from MarketBeat, Artivion currently has an average rating of “Buy” and an average target price of $31.80.

Insider Activity

In other news, SVP Jean F. Holloway sold 8,070 shares of the business’s stock in a transaction on Wednesday, December 11th. The shares were sold at an average price of $30.12, for a total transaction of $243,068.40. Following the sale, the senior vice president now directly owns 153,862 shares of the company’s stock, valued at $4,634,323.44. The trade was a 4.98 % decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink. Also, CAO Amy Horton sold 4,329 shares of the business’s stock in a transaction on Friday, December 6th. The shares were sold at an average price of $29.66, for a total transaction of $128,398.14. Following the sale, the chief accounting officer now directly owns 135,660 shares in the company, valued at $4,023,675.60. This trade represents a 3.09 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders have sold 20,017 shares of company stock valued at $600,007 over the last ninety days. 8.10% of the stock is currently owned by insiders.

About Artivion

Artivion, Inc manufactures, processes, and distributes medical devices and implantable human tissues worldwide. The company provides BioGlue, a polymer consisting of bovine blood protein and an agent for cross-linking proteins for cardiac, vascular, neurologic, and pulmonary procedures; cardiac preservation services; PhotoFix, a bovine pericardial patch; and aortic arch stent grafts including E-vita Open Plus and E-vita Open Neo.